Table 2.

Clinical operational tolerance literature and clinical trials in adult orthotopic liver transplant recipients[9,90]

First authors	Yr/Trial start	Number of patients	Complete IS weaning, %	Median follow-up mo from IS withdrawal	Rejection rate, for acute, %	Weaned patients due to DNM diagnosis
Ramos et al[110]	1995	39	41	15	38.4	None
Devlin et al[144]	1998	18	27.8	> 36	44.4	None
Eason et al[145]	2005	18	5.5	9	61.1	None
Girlanda et al[146]	2005	18	11	84	5.5	None
Tisone et al[109]	2006	34	23.4	45.5 ± 5.8	21.0	None
Assy et al[147]	2007	26	42	6	58.0	None
Pons et al[148]	2008	12	38.0	10-30	58.0	None
Tryphonopoulos et al[149]	2010	23	22.0	87 ± 3.0	5.0	None
Manzia et al[106]	2013	28	21.4	113 ± 20.0	21.0	None
De la Garza et al[150]	2013	24	62.5	14.0	37.5	None
Benitez et al[151]	2014	102	40.2	48.9	59.8	None
Bohne et al[152]	2014	34	50	12	44.1	None
Todo et al[153]	2016	10	70	NA	30.0	None
Manzia et al[107]	2018	75	42.6	78.5	0	None
Shaked[154]	2005 (clinical trial)	275	20.3	NA	5.5	None
Markman[155]	2016 (ongoing trial)	60	NA	NA	NA	NA
Markman et al[156]	2019 (ongoing trial)	NA	NA	NA	NA	NA

NA: Not available; IS: Immunosuppression: DNM: De novo malignancy.